Analysed OCUGEN INC (OCGN:NASDAQ) News Sources
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
16-08-2026
marketbeat.com
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
16-09-2026
marketbeat.com
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
25-09-2026
yahoo.com
Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days
25-09-2026
stocktwits.com
Retinitis Pigmentosa Market Outlook to Strengthen During the Forecast Period (2026-2036) with Growing Focus on Disease-Modifying Therapies | DelveInsight
29-09-2026
yahoo.com
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
06-10-2026
yahoo.com
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
14-10-2026
yahoo.com
What is the current price of OCUGEN INC (OCGN:NASDAQ)?
The current price of OCUGEN INC (OCGN:NASDAQ) is $0.7574.
OCUGEN INC (OCGN:NASDAQ) absolute price change since previous trading day?
The absolute price change of OCUGEN INC (OCGN:NASDAQ) since the previous trading day is $0.049.
OCUGEN INC (OCGN:NASDAQ) percentage price change since previous trading day?
The percentage price change of OCUGEN INC (OCGN:NASDAQ) since the previous trading day is 6.917%.
What is the most recent average sentiment score for OCUGEN INC (OCGN:NASDAQ)?
The most recent average sentiment score for OCUGEN INC (OCGN:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for OCUGEN INC (OCGN:NASDAQ)?
The most recent sentiment for OCUGEN INC (OCGN:NASDAQ) is .
SEC-8K** Filing Available For OCUGEN INC (OCGN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.